Matthew Mabie, MD
Critical Care Medicine · Memphis, TNNPI 1063491280
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.7%), education and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Intuitive Surgical at 54.6% of the total. 2025 is the largest year on record at $4,115, 5.8 times the $705 reported in 2019.
Across 217 payments — averaging $31.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$1K
- United Therapeutics Corporation$213
- Sanofi$194
- Boehringer Ingelheim$186
- Genentech USA, Inc.$185
- plus $1K from 22 others
What the payments were for
- Travel & lodging$1,19518%
- Food & beverage$3,02645%
- Education$2,54138%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $3,695 |
| GSK | 107 | $1,156 |
| United Therapeutics Corporation | 10 | $213 |
| Sanofi | 8 | $194 |
| Boehringer Ingelheim | 13 | $186 |
| Genentech USA, Inc. | 14 | $185 |
| AstraZeneca | 12 | $164 |
| Insmed, Inc. | 8 | $162 |
| Penumbra, Inc. | 1 | $134 |
| Olympus America Inc. | 1 | $88 |
| Grifols USA, LLC | 4 | $81 |
| Mylan Specialty L.p. | 4 | $55 |
| AbbVie(2 entities) | 4 | $49 |
| Sunovion Pharmaceuticals Inc. | 4 | $45 |
| Mallinckrodt Hospital Products Inc. | 2 | $44 |
| ANI Pharmaceuticals, Inc. | 2 | $40 |
| Mallinckrodt Enterprises LLC | 2 | $34 |
| Merck | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Novartis | 2 | $28 |
| Harmony Biosciences LLC | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Pfizer | 1 | $18 |
| La Jolla Pharmaceutical Company | 1 | $18 |
| Amgen | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Shionogi Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,591
- Smart Coil$134
How this compares
$6,762 in reported general payments places this provider in the 80th percentile of 141 critical care medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 387 | $293,792 |
| Breo ElliptaFluticasone/Vilanterol | 202 | $99,576 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 119 | $68,385 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 103 | $63,152 |
| Dupixent PenDupilumab | 14 | $50,367 |
| XolairOmalizumab | 14 | $47,694 |
| Spiriva RespimatTiotropium Bromide | 50 | $29,301 |
| Arnuity ElliptaFluticasone Furoate | 71 | $18,203 |
| Spiriva HandihalerTiotropium Bromide | 25 | $15,874 |
| Bosentan | 12 | $14,934 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 88 | $14,174 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 489 | $11,583 |
| Qvar RedihalerBeclomethasone Dipropionate | 23 | $7,675 |
| EliquisApixaban | 12 | $7,112 |
| BreynaBudesonide/Formoterol Fumarate | 34 | $7,073 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,156 | $479,955779 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $186 | $92,453153 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $16 | $14,93412 claims |
| PfizerEliquis | $18 | $7,11212 claims |
| AstraZenecaSymbicort | $164 | $5,99026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 141 critical care medicine providers in Tennessee.
Other critical care medicine in Memphis
- Anthony MattoxMemphis$33K
- Nathan WildsMemphis$19K
- Robert AguillardMemphis$11K
- Kimberly MarshMemphis$11K
- Paul DeatonMemphis$10K
- Garrettson EllisMemphis$9K
- Roy FoxMemphis$9K
- Steven WoodsMemphis$6K
- William RichardsMemphis$6K
- Michael MundayMemphis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.